InvestorsHub Logo
Followers 25
Posts 1336
Boards Moderated 0
Alias Born 11/15/2016

Re: None

Friday, 05/19/2017 9:27:06 PM

Friday, May 19, 2017 9:27:06 PM

Post# of 203913
I'm hearing more and more about the multiple myeloma study ongoing by OWCP. For those who don't know, this is being head up by a very good doctor who has been involved in many different studies for multiple myeloma. Be watching for comments from her in upcoming 8-ks, regarding this study as this will definitely be a pps mover for this stock. It's also mentioned in the 10q about getting this ready for orphan drug.

A big bio pharma partnership could be announced in the next 6 months so it can be moved too orphan drug after the first of the year. I just say that because orphan drug is an expensive process!

I'm staying long here folks, financial freedom is always in your grasp with good DD!

Here's a part from the 10q about the good DR.



Dr. Merav Leiba, Head of Multiple Myeloma Outpatient Clinic and Multiple Myeloma Research Lab at Sheba's Hematology Institute, led the in vitro tests on multiple myeloma. Dr. Leiba, a specialist in Internal Medicine and Hematology, was a postdoctoral fellow at the Jerome Lipper Multiple Myeloma Center at Dana Farber Cancer Institute, Boston, Massachusetts (2006-2008). Dr. Leiba has participated in numerous clinical and investigational studies aimed at developing novel drugs for multiple myeloma